MYC and lymphoma: In patients with double expressing lymphomas, where co-expression of MYC with BCL2 on immunohistochemistry are detected without associated translocations identified on in-situ hybridization, CNS recurrence risks can be as high as nine percent as compared to two percent in non-expressors [25].